000 | 01917 a2200589 4500 | ||
---|---|---|---|
005 | 20250517034058.0 | ||
264 | 0 | _c20160603 | |
008 | 201606s 0 0 eng d | ||
022 | _a1399-3003 | ||
024 | 7 |
_a10.1183/09031936.00008115 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aDeschildre, Antoine | |
245 | 0 | 0 |
_aReal-life long-term omalizumab therapy in children with severe allergic asthma. _h[electronic resource] |
260 |
_bThe European respiratory journal _cSep 2015 |
||
300 |
_a856-9 p. _bdigital |
||
500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 |
_aAnti-Asthmatic Agents _xadverse effects |
650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
650 | 0 | 4 |
_aAsthma _xdrug therapy |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInjections, Subcutaneous |
650 | 0 | 4 | _aLong-Term Care |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aOmalizumab _xtherapeutic use |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aMarguet, Christophe | |
700 | 1 | _aLanglois, Carole | |
700 | 1 | _aPin, Isabelle | |
700 | 1 | _aRittiƩ, Jean-Luc | |
700 | 1 | _aDerelle, Jocelyne | |
700 | 1 | _aAbou Taam, Rola | |
700 | 1 | _aFayon, Michael | |
700 | 1 | _aBrouard, Jacques | |
700 | 1 | _aDubus, Jean Christophe | |
700 | 1 | _aSiret, Daniel | |
700 | 1 | _aWeiss, Laurence | |
700 | 1 | _aPouessel, Guillaume | |
700 | 1 | _aBeghin, Laurent | |
700 | 1 | _aJust, Jocelyne | |
773 | 0 |
_tThe European respiratory journal _gvol. 46 _gno. 3 _gp. 856-9 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1183/09031936.00008115 _zAvailable from publisher's website |
999 |
_c24945293 _d24945293 |